Offre n°2048
Context:
Metastatic Melanoma is one of the most aggressive form of skin cancer. Combination of targeted therapies or immune checkpoint therapies have increased the Overall Survival (OS) of patients with metastatic Melanoma (MM). Presently, on going trials consider the use of tri-therapies to extend the time of patient OS. Adjuvant therapies are also under investigation.
Issue:
Propose a new class of therapy: RNA-targeted therapy to the ‘non-responders’ or ‘resistants’
Increase the duration of the survival of patients with metastatic melanoma.
Propose a new target for other types of melanoma (uveal, mucosal)
Solution:
Scientists have identified a highly expressed mRNA that dampens the tumor suppressor activity of a miRNA. They propose to restore the activity of this ‘natural brake’ by avoiding miRNA sequestration. They use with success very specific Target Site Blockers (TSB, 16 modified nucleotides single strand).
The offer includes:
- a companion test to predict the miRNA sequestration: 3 parameters are tested (one SNP and the expression level of two mRNA).
- A RNA-targeted therapy: TSB are injected sub-cutaneously, vectoriization is not required. They restore the tumor suppressor activity of a given miRNA in melanoma cells and consequently abolish cell proliferation.
Equipe Expression des Gènes et Oncogenèse (GEO)
UMR 6290 - IGDR
EP : EP13306524 - filed on the 11-06-2013
WO - DE,FR,GB,US
Recevez les prochaines offres qui correspondent à vos besoins.
Conformément à la loi Informatique et Libertés du 06 janvier 1978 modifiée (voir Règlement Général sur la Protection des Données du 25 mai 2018), vous disposez d’un droit de rectification, d’opposition, d’effacement et portabilité de vos données. Vous pouvez exercer ce droit par email à l'adresse dpo@ouestvalorisation.fr. Pour en savoir plus sur notre politique de Gestion des données personnelles, vous pouvez consulter notre politique de confidentialité.